We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
Novazzi, FedericaSecondo
;Genoni, Angelo;Dentali, Francesco;Gasperina, Daniela Dalla;Baj, Andreina
Penultimo
;Maggi, FabrizioUltimo
2021-01-01
Abstract
We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
EID-Protein Escape Mutation Q493R after Treatment for COVID-19 - Volume 27, Number 10—October 2021 - Emerging Infectious Diseases journal - CDC.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
327.15 kB
Formato
Adobe PDF
|
327.15 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
